Search Results - "Vanderstichele, A."

Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors by Landolfo, C., Achten, E.T.L., Ceusters, J., Baert, T., Froyman, W., Heremans, R., Vanderstichele, A., Thirion, G., Van Hoylandt, A., Claes, S., Oosterlynck, J., Van Rompuy, A.S., Schols, D., Billen, J., Van Calster, B., Bourne, T., Van Gorp, T., Vergote, I., Timmerman, D., Coosemans, A.

“…To estimate the diagnostic value of tumor and immune related proteins in the discrimination between benign and malignant adnexal masses, and between different…”
Get full text

Preoperative c-reactive protein and thrombocyte count as potential markers for longterm survival in ovarian cancer by Braicu, E.I., Sehouli, J., Richter, R., Vergote, I.B., Concin, N., van Nieuwenhuysen, E., Achimas, P., Berger, A., Fetica, B., Mahner, S., Glajzer, J., Papadia, A., Woelber, L., Gasparri, M.L., Vanderstichele, A., Benedetti Panici, P., Mueller, M., Ruscito, I., Zimmer, J., Woopen, H.

Get full text

OC20.01: Can determination of immune cells help in the preoperative ultrasound assessment of ovarian cancer? A pilot study by Coosemans, A., Landolfo, C., Baert, T., Vanderstichele, A., Froyman, W., Busschaert, P., Vergote, I., Van Calster, B., Timmerman, D.

Get full text

Metastasis-directed therapy for oligorecurrent prostate cancer: Oncological outcomes of a tertiary referral centre by Devos, G., Vanderstichele, A., Van Eecke, H., Berghen, C., Muilwijk, T., Roussel, E., Clinckaert, A., Albersen, M., Hendrik, V.P., Everaerts, W., De Meerleer, G., Joniau, S.

Get full text

Patient and region based accuracy of PSMA PET/CT in patients undergoing salvage lymphadenectomy for lymph node recurrence following primary treatment by Devos, G., Vanderstichele, A., Van Eecke, H., Berghen, C., Muilwijk, T., Roussel, E., Clinckaert, A., Albersen, M., Van Poppel, H., Everaerts, W., De Meerleer, G., Joniau, S.

Get full text

Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-sensitive recurrent ovarian cancer by Loverix, L., Vanderstichele, A., Olbrecht, S., Van Niewenhuysen, E., Van Gorp, T., Han, S.N., Salihi, R., Concin, N., Neven, P., Busschaert, P., Lambrechts, D., Vergote, I.

Get full text

Ultra-Sensitive TP53 Sequencing for Cancer Detection Reveals Progressive Clonal Selection in Normal Tissue over a Century of Human Lifespan by Salk, Jesse J., Loubet-Senear, Kaitlyn, Maritschnegg, Elisabeth, Valentine, Charles C., Williams, Lindsey N., Higgins, Jacob E., Horvat, Reinhard, Vanderstichele, Adriaan, Nachmanson, Daniela, Baker, Kathryn T., Emond, Mary J., Loter, Emily, Tretiakova, Maria, Soussi, Thierry, Loeb, Lawrence A., Zeillinger, Robert, Speiser, Paul, Risques, Rosa Ana

“…High-accuracy next-generation DNA sequencing promises a paradigm shift in early cancer detection by enabling the identification of mutant cancer molecules in…”
Get full text

817P Response to olaparib monotherapy in relapsed ovarian cancer by HRR gene mutational status and HRD scarring analysis: Results from the randomized phase II CLIO trial by Vanderstichele, A., Loverix, L., De Vogelaere, C., Heyrman, L., Van Gorp, T., Van Nieuwenhuysen, E., Han, S., Olbrecht, S.J.A.R., Berteloot, P., Neven, P., Schepers, R., Busschaert, P., Goossens, D., Lambrechts, D., Vergote, I.B.

Get full text

964PPreoperative c-reactive protein and thrombocyte count as potential markers for longterm survival in ovarian cancer by Braicu, E I, Sehouli, J, Richter, R, Vergote, I B, Concin, N, van Nieuwenhuysen, E, Achimas, P, Berger, A, Fetica, B, Mahner, S, Glajzer, J, Papadia, A, Woelber, L, Gasparri, M L, Vanderstichele, A, Benedetti Panici, P, Mueller, M, Ruscito, I, Zimmer, J, Woopen, H

Get full text

Abstract P6-05-05: Triple receptor comparison between primary breast cancer and metachronous or synchronous liver metastasis by Tuyls, S, Brouckaert, O, Vanderstichele, A, Vanderhaegen, J, Amant, F, Leunen, K, Smeets, A, Berteloot, P, Van Limbergen, E, Weltens, C, Peeters, S, Vanbeckevoort, D, Floris, G, Moerman, P, Paridaens, R, Wildiers, H, Vergote, I, Christiaens, M-R, Neven, P

“…Abstract Background: Decisions about systemic treatment in women with metastatic breast cancer are currently based on the presence of estrogen receptors (ER),…”
Get full text

Abstract P2-10-12: How well predict the 2011 St Gallen early breast cancer surrogate phenotypes metastatic survival? by Vanderstichele, A, Brouckaert, O, Tuyls, S, Amant, F, Leunen, K, Smeets, A, Berteloot, P, Van Limbergen, E, Weltens, C, Peeters, S, Moerman, P, Floris, G, Paridaens, R, Wildiers, H, Vergote, I, Christiaens, M-R, Van Calster, B, Neven, P

“…Abstract BACKGROUND: The five prognostic surrogate phenotypes, defined by the 2011 St Gallen consensus, predict metastatic relapse following early breast…”
Get full text